Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Countries Slam Transferable Exclusivity Voucher Proposal

Executive Summary

A group of EU member states has written to the European Commission saying that an exclusivity voucher scheme intended to stimulate R&D into new antimicrobials will stifle innovation by competitor companies and push up costs for national health systems.

You may also be interested in...



Novel Vaccines Among Wide-Ranging EU Plans To Boost Health Threat Preparedness

Two documents published by the European Commission outline proposals to prepare for future health emergencies such as pandemics and the impact of antimicrobial resistance, with next-generation vaccines and novel or repurposed therapeutics high on the agenda.

EU Wants Legislative Review To Support ‘World Class’ Pharmaceutical Industry

The European health commissioner has told members of parliament that a balance needs to be struck between promoting innovation and maximizing access to medicines across the EU member states.

Results Imminent From Sweden’s Pilot Of Novel Antibiotic Reimbursement Model

If successful, a new Swedish model for reimbursing antibiotics that involves guaranteed minimum annual revenues for companies could be tested on other kinds of products.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147398

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel